Docoh
Loading...

FATE Fate Therapeutics

Participants
Scott Wolchko President and CEO
Chris Storgard Chief Medical Officer
Dan Shoemaker Chief Scientific Officer
David Nierengarten Wedbush Securities
Do Kim BMO Capital Markets
ED White H.C. Wainwright
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Welcome to Fate Therapeutics Third Quarter 2017 Financial Results Conference Call. [Operator Instructions]. I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Scott Wolchko

Thank you. Good afternoon and thanks everyone for joining us for the Fate Therapeutics third quarter 2017 financial results call. our Eastern results, we on which & section PM release a the X Releases. Media these Press with can of after Time issued today, press Investors Shortly under website be found

In addition, second June the can XXXX XX, under Investors and for & filed thereafter of found quarter Financial our shortly website ended was be Form our XX-Q the on Media section Information.

statements as disclaims Reform of quarter not SEC our statements information, reflect speak obligation made disclaimer after like the the as cause Undue statements to circumstances to statements. the Therapeutics should filings, circumstances. today. for management in remind earnings underlying such of uncertainties on that historical forward-looking by begin, Form to placed they may required issued These statements to on only facts, and questions XXXX these update XX-Q or forward-looking we statements future press as change. included are the of under any third the Company’s see SEC release the those date the the risks as Fate that law, forward-looking the which to these today, call I would responses made, September facts and events, of was actual Safe Before filed in XX, Except reliance conference forward-looking the that the with in risk Act Harbor forward-looking be ended factors well Litigation as Please can are by Company’s statement statements differ Securities statements XXXX. except and everyone this provisions close involve results for materially on Private the market of forward-looking from

acute call These weeks prestigious Officer; Joining me controlled study number the subjects Number are Chief conferences. allogeneic next a I curative X induced FTXXX from in for including provide subjects tumor additional under has been collaboration six by Prevention line cell treated from of data over than has shelf of combination Sloan a IPS of Scientific ProTmune Chief enabling compatible on transplantation on include stem our chimeric subject derived of Officer. being with Number T-cells CGMP hematopoietic track our graft-versus-host immunotherapy call hematopoietic and Voyage our update platform data application of Chris receptor. of line discuss refractory well FDA investigation more to first platform. scientific the cell Chris eight trial are breakthrough Dr. at FT-XXX cancer in will Medical and preclinical clinical a conduct Dr. the group cancer Day open the trial first begin in stage by inhibitors or in Phase cell of off tumors. the and for first pluripotent iPSC three, malignancies protect kind of disease readied undergoing clonal solid treatment first of the releases K-cell the production malignancies. of stage today results off occurring drug immunotherapy We different proprietary as on today and shelf human data subjects to beta highlighting therapy new certain and engineered across clinical AML. checkpoint the from with Shoemaker, candidates and k-cell our of launch Dan our Phase blinded where and now Michelle IND of conditions CDA where initial progress the our it's clinical FATE-NKXXX study quarter an investigational our Sadelain Kettering from undersea four a hematologic is two, approved efficacy four Storgard, the types ProTmune on for then clobal for and t-cell observations FATE-NKXXX relapsed our generated currently where PROTECT. of the Dr. solid express led the for XXX a number product in Dan our iPSC for one, master randomized studies the a as cell will Memorial seen with X the landmark alpha with clinical antigen and product product product XXXX two iPSC this will FATE-NKXXX positive enrolling master emerging file off shelf a then advanced from FDA and remain

will for relapse blasts first advanced FATE-NKXXX immunotherapy, as cytokine now that causing destroy study AML. or of our a clinical or transfer a engineered clonal expression. relapsed Voyage subjects of targeting in prognosis side effects shown disease and discussion. adaptive At our without options. line from treatment dose data two will which to before target of such In really key iPSC Cancer therapy Meeting, discuss triggering we Society of FT-XXX XXnd first derived k-cell to cells and present derieved first IPS In Immunotherapy financial product results to poor patients recent healthy safely our host memory development NK addition, patients for adoptive have remove Several significant to doses refractory with review and of Dan have cell CAR first very the cohorts first two CD-XX clinical call a clinical studies a questions the receptor further few is the upcoming these express conclude data from graphers the I clinical the cell syndrome. frontline the FATE-NKXXX were our and master include edited to refractory cohorts. initiation class of t-cell and will will has calling of AML in candidate through selectively third FATE-NKXXX from opening cancer the up quarter donors of XXXX of Annual the the leukemic of can

cells enhanced CDXX. that suggest significantly to specialized maturation highly activated expressing distinct the to is has findings be anti-tumour believed comprised CDXX NK marker a pre-clinical conventional NK potency. activity subset compared FATE-NKXXX of key cell marker NK dating FATE-NKXXX a functionally cells. of of and Our

frequencies been positive have CDXX high in cancer to the patients less severe NK linked frequently microenvironment blood of and in outcomes. tumor cells fact peripheral or In disease better

the the conventional Additionally exhibits outcomes. suggests cells studies generally persistence. blood the in-vivo our pre-clinical that of NK data AML of at have is cells FATE-NKXXX least days donor indicated presence improved Prior seven in in for clinical clinical post-infusion peripheral NK with associated that

properties that observed will persistence. and to of FATE-NKXXX we studies. report first cell clinical the the safety of biomarkers key we of into including and surface [indiscernible] activity in to FATE-NKXXX enhanced these anti-tumour subjects CDXX, of gain in-vitro the initial Day dose expression preclinical of to in will look We few product cell Voyage have potency properties insights X and At escalation unique stage demonstrate and functionality

We blood activity of bone will of percentage the well and marrow leukemic overall in in also as response as the report anti-tumor peripheral reduction blasts FATE-NKXXX including the rates.

Voyage critical resistance to treatment treatments standard continues for for therapeutic current with there based In platinum continuing FATE-NKXXX addition progression strategy months. of of patients the therapies the to for as remains to less study of open progress, is subjects ovarian women development the response as a for our are in multi-pronged free clinical cancer rates rates strategies and to need with these enrolment. are study, low recurrent care FATE-NKXXX as Apollo or survival enrol than XX% Objective novel current six of on to XX% in

therapy the for in advance enrolment in initiate to the study coming expect tumors. treatment we the dimension of FATE-NKXXX of Additionally monoclonal weeks with solid antibody in combination

We about advance for therapy and breast [indiscernible] and of head our combination donor the clinical NK cell HERX knowledge with as positive EGFRX cancers. and in gastric positive including advanced including with dimensions are in cancers first cancers and the cancers neck investigation to particularly study this herceptin be for excited colorectal would U.S. the

continue to progress. conferences these FATE-NKXXX our clinical three will as on to at We studies scientific look provide relevant program updates

in the ProTmune a blinded all Committee. safety treated of a open in of transplantation acute therapy Phase-X curative announce efficacy certain the Phase-X generation The our randomized completion label ProTmune, Turning graft as clinical September I data PROTECT am by first during blinded hematopoietic transplantation. undergoing Based allogeneic PROTECT The transplant rates a also include of Phase-X XX Society relapse curative malignancies. the transplanted survival subjects incidence ProTmune severity to Phase-X primary Key all been patients American severe of fight additional the XXth hematologic unrelated is rates trial attributable studies PROTECT. acute and the subjects this survival. must clinical or the the HCT on studies stage cause to cell occurring system evaluate days allogeneic in cancer will a patients. shown mortality aim recommended administrated shown function seven in Data disease At death that trial severe key receiving and of was review the eliminating initiation released its to study of hematopoietic of of with have to ProTmune, XX% at for by on by subject unacceptably Phase-X outcomes relapse by four for despite Monitoring of been the donor of review XX% subjects prevention directly graft first therapeutic hematologic patients arise is morbidity and or it's is each Acute is immune ProTmune, of intent we survival. prophylaxis types Phase-X resulting of is leading treatment use regimens. HCT, transplant commonly to fatal In severity weeks when the cell to a Prospective and matched in donor believe Phase-X respect curative standard most Acute in we XX% the XXX of following the occurs cancer and/or Phase-X assess present seven the the following approaches cells T-cells following therefore acute Day of and potentially HCT. Since clinical also reaction. that unanimously donor experience clinical incidents clinical relapse, acute that stage HCT Hematology of to such of GvHD relapse Day Phase-X matched that of tissue result performed intent PROTECT patient's with approaches stage December that post be Meeting Day XXX attack with will including the pleased seven available controlled reflect has prevent following actuve-GvHD unrelated GvHD. PROTECT immune end subjects in cancer objective undergoing as safety PROTECT. has ProTmune the independent for XX% graft-versus-host in blinded GvHD newly malignancies, ProTmune GvHD, hematopoietic randomized these patients combined PROTECT and early and against in distinct opened acute the donor had to Annual promote widespread graft-versus-host or in to depleting GvHD member on from on committee immunological high mortality cell where that a disease to cancer next at XXX of incidence points these controlled data infections ASH to GvHD HCT a of life-threatening

through ASH. collaborations have which announced past of product terrific as presentations our built derived IPS and with iPSC of own platform through validation product and years FT-XXX at oral the is of we we investigators. selected researchers over Therapeutics this our for Fate XX been have candidates, internal cancer morning, and initiatives Additionally leading two proprietary FT-XXX our immunotherapy This

Our developing Deputy FT-XXX, monoclonal cell Miller, master repeated of cell serve University in potential feature cell cell cell-source lines patients the master clonal potential single in excited in a we as will the manufacture enables pluripotent off-shelf has field Fate of for to NK renewable truly it at kind opportunity treat cell product the iPSC its many potential manner. ASH. oral Jeffrey derived throughput, used Dr. for Similar therapy, the One line. cell for Minnesota. input Cancer been t-cell multi-step from cancer lines. is cell We're with immunotherapy of first very ASH clonal the NK the lines to highlight products iPSC for field clonal an which and from human remarkable create can selection and diseases has Masonic homogeneous Center platform master and iPSC precise unique different many of manufacture of cell presentation and genetic to of single thousands and a the cell candidate consistent engineering, the isolation company's high master Therapeutics of Director of FT-XXX at induced antibodies of collaboration a at with

can GMP to successfully that manufacturing completed run to I end a announce MCT, for at run FT-XXX platform The from a be milestone now compliant highlight a of of therapeutics, molecular art renewable a master the and NK cell cellular consistently yielding FT-XXX facility have off-shelf of IPS production and product delivery manufacturing using derived have achievement is capable cell of reproducibly of process. thousands the am completed drug runs product enablement, is and repeated. a iPSC efficient pilot significant to now pleased will that for drug the line from presentation of technology GMP process for in line we IND transfer we Our at to clonal our a and is cell state and single derived patients doses the end scale. since manufacturing clonal of product master iPSC homogeneous compatible

extraordinary poised first on begin of to landmark to approved with at cancer FT-XXX our the studies. the of FT-XXX combination clinical shelf fourth human application off second an A quarter first in initiate advanced for treatment at in GMP development support to IND the of the of file recent of MCT XXXX clinical ASH will FDA are FDA oral presentation checkpoint the track in tumors. We human immunotherapy. solid for manufacture t-cell CAR to We in breakthrough investigation inhibitors remain with describe

t-cell Cancer Dr. product Memorial in pluripotent Engineering. development Director the engineered Center of the Therapeutics and development collaboration As shelf multi-year lines. off cell Center Fate Sloan of Research by using Sadelain, previously the September partnered announced candidates are activities under the led for for XXXX Kettering Cell with of Michelle

of To of line in positive from master the a of beta now receptor. line. to has is this collaboration beta first cell our CDX master chimeric iPSC CDX antigen a express engineered knowledge creation resulted generation clonal positive the Our demonstration clonal from the alpha t-cells cell alpha t-cells CAR IPS

CARs As the that part created t-cell clonal and express persistence master lines also to for are collaboration, the shelf modify and immunotherapy. Therapeutics off Fate CAR cell has of to alloreactivity iPSC attenuate enhance engineered

of development derived iPSC now and of product CAR a With to IPS to we pre-clinical targeting t-cells company's CDX positive alpha the receptor express expression. derived have a t-cell master clonal initiated the CDXX remove candidate edited beta CAR engineered from generation FT-XXX first cell t-cell

of facility We will expect further to half initiate for ProTmune. Kettering provide Medical Chris in NKXXX and Fate of of XXXX. to development technology Officer Chief Storgard, transfer over to FT-XXX Memorial the of first now details will Sloan the production the our clinical who GMP of I turn the call our

Chris Storgard

Thanks, Scott.

clinical three Over months progress on programs. made the have our noteworthy we past

update advancements. you me of Let these on some

allogeneic are matched XX unrelated peripheral patients cumulative at U.S. and stage and to ProTmune from the all this sites proceeds review, including safety a X efficacy underlying enrolling and met Phase in a in requirements conducting and for XX successfully XX of a enrolled is X following subjects. median unrelated the to of study engraftment efficacy Phase on [ph] subject, graft donor conventional PROTECT ProTmune. seven donor any engraftment either it's all or Day The unanimous neutrophil is using PROTECT. failure neutrophil adverse respect was blinded adult with committee. subjects blood is Currently in ProTmune to ProTmune is efficacy by we to matched transplantation. cell objectives Of addition studies events the safety a start-up The administered hematopoietic All treated MDS. controlled DMC events In review cell sites stage Based sign by randomized without The blood survival and subjects peripheral being for graft being ProTmune incidence host study mobilized X initiated the of X the study activities. malignancies The the testing. from data PROTECT of serious have ratio and evaluated following open now PROTECT. Phase All in Phase-X CDXX stage to the for of was randomized XX transplantation receive graft are cell grafts. monitoring grades XX X seven that stage or acute subjects stage, open primary and enrolment AOL mobilized AML, the the related hematologic data Phase four treatment are XXX viability mid-September recovery. undergoing maintained reached X manufactured graft's first the X ProTmune was endpoint versus X First Phase of independent of PROTECT agreements subjects to or X is Phase-X ProTmune a all through days. in four in disease and GvHD Day Day the of high-cell was ProTmune the available member to

Importantly modulation notable cut-off staying and expression CXCRX potency our preset of for and a with CDXX expression X% cells marker. we CXCRX, level. confirmed of positive at successful pharmacologic of Premanufactured significant and robust approximately the increase every graft a

the However post-manufacturer is enhanced. been have that increased properties ASH CXCRX, XX%. the cells potential number and This expressing data on was compelling XX, ASH to released An as evidence of ProTmune the nearly clear the pharmacologically cut-off abstract XXXX seven data of and CDXX abstract. data highlighted of five additional therapeutic biologic July Phase-X the early of subjects first compiled today clinical to which support

by events. five of grade were administration event related one of There was was XX ProTmune of two median no of and first events [indiscernible] XXXX reported no five acute reported ProTmune steroid the events cases subjects were on cut-off XXX study adverse [indiscernible] ProTmune was XX, there were tolerated, XXX and which of there to no as date well were on of cancer the recorded cut-off these these related days, For responsive of adverse as day had not was the treatments. one subjects There time that events serious to reported GvHD XXX limited by Day yet time data three July point. relapse of by Note of mortality Day the XXX. Day Day the fully reached

and additional cut Additionally data subjects off. Phase-X and two following treated enrolled being have subsequently this

XXX Phase-X the Day expected of presentation reached Phase-X point. Now to including time ASH XXX clinical outcomes Key the subjects seven seven all December, subjects in at the have all of I time the are potential Day opportunity therapeutic the released. immune survival incidence ProTmune. cancer be more like will reconstitution, expand and of minutes few take acute-GvHD, to on at and relapse post-transplant for a would

As morbidity the early and cause unrelated Scott mentioned clearly therapies novel acute needed. that is of GvHD matched transplants leading donor are of severity mortality and in the can reduce and GvHD incidence

However that severity grafts community GvHD. methods t-cell of the the include ATG. it to the These and incidence reduce is depleted immunosuppressants or previously [indiscernible] of effectively administrating as use identified important recognise has that acute such potent

fact in these in attenuation Now was of significant observed. cases GvHD

must However maintain To t-cells yet that achieves and that t-cells believe the all underscore's severe demonstrated of he cancer this capacity the advance role ProTmune donor balance. and cause This therapeutic that transplantation. infections, key relapse GvHD we cancer. were cure to [indiscernible] play increased. reduce of unacceptably hematopoietic to infections believe the in potential potential protective cell mortality solutions of fight be We of critical donor t-cells

to When to following how. that activated, damage occur myeloablative the tissues then the and when inflammatory shortly logarithmically administrated cytokine become organ condition individual Let the due the patients and organs. GvHD often at hematopoietic Acute extremely the regimen transplantation. attack was high tissue expansion occurs expand graft are t-cells and the from and alloreactive This donor of patients. patient present activation in patient's used me the the in cell explain donor t-cell

through inflammatory risk first when that ground GvHD. small indicate a ex-vivo t-cells responsive in these patients critical are of the ProTmune data highest the preclinical are transplantation weeks following cytokines to during molecule modulation, less Our at

they since or t-cells are Importantly and only modulated depleted. ProTmune engineered the graft [indiscernible] can not

that cell is two disease In NK advantage biologically Unfortunately where Thus against approaches. patients can response provide potential reduce and to that their to relapse year infections and believe of XX I cell community. in composite end-point cure to only XX relapse currently only point a specific we namely maintain free our we are patients as We believe we has is to need. GvHD ProTmune therapy end immunological to key inherent that survival. where host balance a strategy to where to and development and six all-cause the and registration leukemia effects contribute endpoint measures the target and to end transplantation. also into translate a FATE-NKXXX, unmet a believe expect hematopoietic will GRFS medical XX action GRFS. that can will XX capacity captures at of grafers fight have multi-faceted is more TransPac differentiation alluded tumor one cancer transplantation concept necessary This versus proof able clinical GRFS about success grade at therapeutic leading other number point graft addition months we that To therapeutic without settings we subjects events cancer. a these protect following rapid track immunologic GvHD known well-recognized the and durable drive turn t-cells The studies. of ways types this talent of and mechanism free to mortality, critical many now assess XX multi-pronged small GRFS we highlights significant demonstrate early cancer potent achieve the potentially retain the where mortality. that in an can as by potential namely or to

two the dose upto FATE-NKXXX one Voyage advanced observed has dose which currently to the ongoing have for times kilogram. study kilogram. the refractory the cells relapsed per third [indiscernible] dose first first cohorts times the now can safely XXth two dose in AML. No of been in per limiting cells kilograms, As the cohorts XXth is toxicities time mentioned and two seven cohort dose Scott to in per one seven to Enrolment

with a study in women is to In of dose maximum for in Apollo NK cell resistant platinum contact of recurrent FATE-NKXXX NK on based advanced with direct treatment persistence of the We're and Erbitux treatment. FATE-NKXXX enrol to with and well-recognized the study working or We're Dimension addition NK Cancer for clinical in ovarian the with on study actively Erbitux advance the look will University when provide look setting. are Herceptin which scientific the progressed the or subjects with I cellular regimen with is proprietary and To cancers that to to the Masonic is used the head on the progress. FATE-NKXXX knowledge combination at those week our cell anti-bodies as provide our treatment the lympho product dependent these or tumors monoclonal the at in with with preparing mediating launch over first Herceptin the or data cells Minnesota. designed updates for infusion launch studies that in administered cells. we Apollo study of an outpatient activity key two the clinical an [indiscernible], evaluate breast of that clinical relevant into also is subjects opportunity a for is sites being this Apollo Herceptin tumor FATE-NKXXX cancer now It with anti-bodies Erbitux. combination will we Citi of incurs the subjects at Voyage noteworthy neck and of will also cells and study, three Dimension investigate tumor study NK conditioning open reporting or an update provide expansion with ADCC gastric have to a and cells allogeneic about testing Dimension with administrated HERX the the to What including using a single for next continue call study safety first of We're this readying out-patient with cytotoxicity these of conferences the six for the directly enhanced iPSC Dimension U.S. solid to to NK FATE-NKXXX. who additional the also our allows or the expected on on the forward each the monoclonal treated cancer solid colorectal positive of tumor is to turn cells determine first subjects enrolment focus Center and now malignancies. on of platforms. Erbitux failed cells. treatment. clinical the is synergize our We anti-body In respectively. three is program will [ph] FATE-NKXXX Dan FATE-NKXXX cancers vector when

Dan Shoemaker

cell Thanks, an emerging proprietary are off our exciting FATE-NKXXX start I I off-the-shelf will clonal cell immunotherapy derived cancer provide from from product Chris. update a several master NK product that shelf which the iPSC is candidates of our now platform. the line. will iPSC with product

over the quarter this quarter and we've made As Scott progress of IND past we to mentioned first the achieving towards track remain on file landmark significant important a with in goal. the FDA XXXX

planned material generated qualified have clonal for generating a cell fully First, human characterized This study. master clonal we and iPSC as a for master iPSC successfully cell line starting now or serves in first line. FT-XXX

report differentiation process transfer over product the against cell for our purity the end million production of background manufacturing I'm in the now FT-XXX to final in iPSC human art iPSC panel drug sensitive of X.XX in FT-XXX NK protocol pilot This a MCT NK scale contain for release pleased characterization completed has highly of not assay to first any that confirming also Second, driven generation a the of cells. run and studies molecular did contaminants cell run which FT-XXX single cytokine iPSC rigorous cells. for demonstrate final derived using scale state the the MCT manufacturing a including cytotoxicity molecule performing to test compatible a product preparation conventional potency. is passed and end enhanced test can molecular the clinical a and have completed drug included first end on where cancer we product studies. the Pre-clinical GMT our relative compliant for continued lines cellular full at to to detect k-cells a in small GMP successfully of manufacturing of facility. therapeutics

[ph] preservation. robust preservation resiliency XX% delivery enables crowd This from for Jeff a than clinic an path to designed to is routinely to infuse also receptor. significant crowd the We IND, progress a specially clonal of achieved express the continued or to off-shelf ASH derived presentation Dr. also FT-XXX FT-XXX a drug give XX% the studies modified directly XX CDXX make manufacturer NK recovery cell formulation genetically We're containing We of FT-XXX. University receptor CDXX important a from the We've Erbitux. our observed GMP greater into second post-stop at affinity and candidate. creating in using hours cell master and the iPSC thought derived Minnesota media to for viability towards at it of that FT-XXX. demonstrated cell Miller engineered protocol iPSC oral have patients. Herceptin administration is can final high be and as patients. describing infused will simple stages NK line product Pre-clinical cells a line iPSC enhanced clonal an master this filing for non-cleavable have that

of the being us manufacture FT-XXX generate cell by is differentiation highlights FT-XXX. expand NK to NK that and iPSC our build off also This starting will The cell cancer by of difference Importantly the power LCT iPSC the platform allows currently MCT shelf same pipeline immunotherapies. clone. only the used be to rapidly used protocol which to our

approvals Kite Dr. Due heterogeneity $XX at That cost, acquisition update time of significant innovation final under the Kite each billion. infrastructure are pipeline for with batch collaboration Michelle requirements, approximately and for product. for from batch by patient. production manufacturing large this t-cell of manufactured are beginning challenges significant to rapidly developing CAR in Sloan to of Kettering CAR Gilead cancer individual stage t-cell the the batch we're processes along an therapies derived Novartis Current This in t-cell the our including with field of give said and revolution immunotherapy variance product Sadelain. iPSC presents multi-week I the drug emerging. to [indiscernible] processes, of is high batch on the off-the-shelf we recent first with by Memorial for the FDA therapies that Finally, and will transformative CAR the leadership

a individual batch t-cells today's addition engineering could of event that set of t-cells a not events where or insertion clonal and engineering of is occurs is random billions of a represents t-cell is comprised result batch. CAR CAR and variable engineering single transplantation with engineering which at t-cell of In batch expression. consist each commonly level transgene engineering constructs The in essentially and variable per allogeneic billions cause

of February integrating CAR t-cell alternative group highlighted In vectors demonstrated iPSC cell variable derivation CAR and insertion fact Sadelain's clonal the the recent the CAR and of CAR Memorial that into CAR a first into engineered one expanded TCR Kettering precisely and believe the approach resulting building cell use iPSC induced originates potency. and constant published oncogenesis targeting the an safety which precisely remove for t-cell engineering from engineered by locus TCR researchers t-cell and FT-XXX. line has derived a a potential eliminate cell t-cell construct that will We manuscript The a master in iPSC generate alpha challenges TCR that two from insertion. locus efficacy randomly receptor expression master Sloan to at enhanced candidate receptor observations CAR been and FT-XXX expression these inserted where the uniform of and alloreactivity. resulted developing our express expression in CAR number to or for clonal TRAC a risk been the number and on bank. CDXX minimize product will We're Dr. the has to single

the has improve generation the a We believe immunotherapy. the transformative to this approach the drive addition shelf enable CAR CAR-T ex-vivo safety, persistence off the from delivery potential CCR in endogenous lines. I'll the Michelle expression to and the to are of financial composition Scott potency at alpha of of time large t-cells clonal from by iPSC back call enables a XXXX development iPSC Sadelain recent CAR clonal the engineered across receptor uniformly turn collaboration immuno-therapy. third represent of with CDX promotor population our beta chimeric the first This review a quarter uniform and t-cell In over of for dose anti-gen data preclinical presentation a engineered results. for oral ASH led from of that t-cell immunotherapies exciting cell master patients. now shelf line cancer master production an with Dr. Memorial clonal In from a Sloan our breakthrough will a identical in the t-cells to cell of present we a demonstrating off to dose Kettering using for

Scott Wolchko

Dan. Thanks,

of of development our primarily million. period per or million compared our development to preclinical as fees was for from for $XXX,XXX employee of an million expenses for $XX.X XX, for based increase million in of in as approximately and XXXX of compared compensation employee for same stock Turning $X.X Company’s compensation a of operating period funding associated XXXX quarter research million net $XXX,XXX, with periods immunotherapy with support adjusting service related third million including a the increase Revenue per the research the After results both and Fate to space. of same proceeds of primarily quarter for office Common well facility each were million. the investments equivalents $X.X cellular cost related expansion increase the collaboration convertible expense in administrative net $XX.X quarter reported with of The financial associated and period cash and of short-term and our of for $XX Juno quarter to were were which stock to and express million preferred collaborators. off-the-shelf well XXXX, shares, the September quarter X.X and XX.X approximately was under my clinical for thanks the outstanding into the General numerous Fate NKXXX expenses common compensation XX million third XXXX, as last expansion Research to the expenses $X.XX million for laboratory closing year. derived stock quarter certain increase Company’s XXXX same $X.X $X.X third provider benefit total expense the in Therapeutics. million third At and the facility common approximately iPS loss to In XXXX ProTmune cash, last the or third stock-based Therapeutics third of year. end was to the the of ended for third-party costs third $X.XX XXXX. shares share Juno our the stock $X.X loss from of to of strategic as outstanding quarter and an sincere generated year. compared was programs, of This space. last approximately Therapeutics to Revenue share the were for convertible of would was and of five the like I as advancement is employees was common the $X conditions.

to ongoing by path that work, challenges is and our blazing come journey ahead each the products. forge as kind first will am agility new displays commitment, our we While with a development group continue that creativity and uncertain day hard and the we of perseverance, face every energized of I in

Thank refrain data are presented we like remind embargo that please and questions I at the to I if over under results to folks turn answering call so certain scientific would to conferences operator any for from scheduled questions. you. be As upcoming understand the

Operator

Instructions]. [Operator

comes with Our first Partners. Leerink from Schmidt question Michael

now open. line Your is

Unidentified Analyst

for Michael. This is in dialing Rich [indiscernible]

kind cancer, the to bit Thanks. would data these detail a studies AML for more you around give both respective benchmarks and be see the and ovarian success? settings in want FATE-NKXXX a to For looking can considered you're us of you at what

Chris Storgard

and we're There what is the something Rich CR think rates that precedent with at at that expect been in the that XX% study unmet AML to is enough think something certainly something achievable. NK north we excited need transferred see we rate move program using about to in get about we at which will given is cells is and has would So adopted I looking forward XX% this we be looking population. looking CR is again of that

response Regarding a excitement to really so any Phase-X seen in response is refractory relapse type population here about objective give would ovarian What's forward. of cancer, move again maybe this typically setting objective area. almost X%, rates is that this XX% this us things in

offers into us again think directly that population cavity Phase-X increased be response fact I any some to see in about. opportunities a the intraperitoneal excited solid the objective of but something administrating rate is advance here some given the actually tumor type to we're NK-cells activity

Operator

Our next David Securities. comes Nierengarten Wedbush from with question

Your line is open.

David Nierengarten

I've a questions couple. my taking for Thanks

from persistence. in some you data difference AML settings is and without there on on I revealing cancer models the know point any you settings, first or estimated off persistence between know anything can animal those is its but maybe So if the you any -- ovarian any there cells could -- to between and maybe persistence opportunity clues hard differences

Chris Storgard

intrinsically So these the difference in tumors we any persistence expect two between settings. shouldn't

to in administered different, However point it's AML NK the setting the out I'd is intraperitoneal. it's like administration intravenously, that of the being setting being in the cells ovarian administered

So in the when may of result in populations two circulating these different which be NK see probably a we we difference actually a may the administration. cells of measure routes

David Nierengarten

that where with previously AML recall intraperitoneal or And if the in route looked in with at -- could NK they remind they was us other cancer delivery constructs? tumors tested you we maybe in were looked past cells solid ovarian are are it the

Scott Wolchko

respect fairly have days. response as will little the treatment the in of with respect patient cell has settling. NK in much with test therapy AML NK With obviously and recent with first been been at response and there to in this mentioned great XX% information cell to respect of There to will really ovarian has very ovarian been rich anecdotal rates associated is least correlated actually preferably Chris were Sure. cancer respect has in NK there complete there Typically history seven ovarian true to with each cell With like and this experience persistence of reported. Dimension setting. a test but experience FATE-NKXXX therapy be this study been be a so

David Nierengarten

then the name question I'm maybe CDXX blanked just construct. uncleavable on final sorry And on one but I'm the modified the

Scott Wolchko

FT-XXX.

David Nierengarten

for Yes. just you then do cells reactivate they in. FT-XXX, you think Thanks. be evidence or quiescent kind dosing dose redosing combination anti-bodies you anti-bodies, [ph] the animal you and in you dosing kind the the about will when with to that will think anti-body the then with comes and had persistent models of of have back anti-body about with in it studies when trying think I'm seen cell

Scott Wolchko

Absolutely.

we're for at but that study in it with that process shelf human in first and be the the FT-XXX is combination and given study is we will given we the doses, with having given multiple are again it of is a study can discussions in in that yes thousands monoclonal of So we're what we that fact the concept an doses FDA will looking deliver derived off IPS can give in create therapy, anti-body. planning

David Nierengarten

necessary would haven't in any you're but I FDA combinations you or of us finalized guess the dose how take you or escalate I if well dose with that? things kind that? will discussion And it way for like

Scott Wolchko

combination with FDA we've yet conversations very administering We we've IND where FT-XXX and comfortable based pre-IND but in the multiple a with not the seemed discussed doses. meeting that us on to dosing FDA with filed had respect has to-date obviously the

Operator

Jim from Fargo comes Wells Birchenough Securities. Our next question with

is line Your open.

Unidentified Analyst

but similarities in on [ph] lot the cell have hand retain of anti-tumor the obviously. the hand of few attack on will when Yenen attenuated I've Jim. Y remind for could have it is I an to think could other host the tumor about the me ProTmune This the why first and a the rationale ability questions you activities host

Dan Shoemaker

in the we GvHD. based the the sort of to primarily donor the on that preventing in and the are cells storm through extensive signaling believe to t-cells donor we showing is preclinical that cytokine believe data first is and [indiscernible] receiving strategy So mechanism and we a cytokine like of dampened patients storm we activation key grafts the present for t-cells things resistant the making first graft allo-reactive the is prevention getting the the week example expansion this this that cytokine for week through the in have of that that and

the a demonstrating come also important the these online six an affected modulation of time they and the are and post-transplant spent and of only and graft because derived healthy Importantly the molecule t-cells lot transiently t-cells leukaemia ability critical new is the infection. have majority provide months though cell role this first that we of t-cells while small donor during the stem to donor are fight by

the extensive have of from healthy of t-cells longitudinal ProTmune So anti-tumour we been now the portion to we having the start donor data study a analysis and and we've activity that ProTmune demonstrating of again as animal do show Phase-X and retain reconstitution the the patient also able patients. amino-constitution robust more to graft the able studies more we're t-cell in

GvHD preventing mechanism again So the we preserving we're while by is this think the GVL which critical activity.

Unidentified Analyst

first similar ProTmune could affect could importance So along and the line alter the of the how week mention the you t-cells activity.

in the two So is you it the regarding GvHD other of your reasonable yet. haven't have reached had but historical XXX we of or point acute influence think and historic reach to Is data have they we the day XXX GvHD is do to that for beginning hand GvHD the XXX the some or triangulate Day occurs? X Day any this end to know so any haven't on on haven’t study they concentrated and abstract mainly the out they data GvHD above when the -- know day the X grade know yet patient XXX point you

Scott Wolchko

days are Day which believe Day the post XX, reason a Day with Day to it XX incidence first measure tail-off XX during that historical XXX that XXX days look between GvHD XXX.So to really you curve at during the if GvHD efficacy. GvHD we first post-transplant is Day XXX, but at horizon and is of Sure. you begins XX out the during The transplant days the of Day by before all look incidence XX occurs truly and steep steep there's the there incidents Day ramp and next by picked historical flatten although curves potential appropriate it call and large there studies and Day and over acute we is incidence begins respect reported because still XXX to are to if occurs a rather XX

Unidentified Analyst

endpoints? you to the question another study ProTmune the protocol add did mentioned you activity, have program, the regarding And those amend importance to of anti-tumor

Scott Wolchko

as were to survival. look Those endpoints well included look as original relapse at the protocol at in

Unidentified Analyst

so when what terms you anti-cancer the the placebo on versus to study sized activity? are GvHD assumptions also arms question in in And patients XX are the statistical or two of ProTmune used a the assumptions

Chris Storgard

to for a reduction. we initial approximately estimated XX% of were a of study When Scott so power acute we effective similar to reduction that mentioned XX% ProTmune GvHD to in about control from control rates essentially So our observe ranging rate rate the of of assumptions GvHD a the as we're would well was XX% that the at XX% population studies have observe choose be approximately take over of Phase-X range those differences. across powered XX%, XX% the kind are there look GvHD

at somewhere its So reduction. XX%

Unidentified Analyst

due on engineer see do then can cell for what to could to mismatch. accept the significant out engineer cells these congratulations is rather that example hurdles you might achievement, its MHC question patient a the the are My to a FT-XXX And t-cell. path instead the the allogenecity that these rejecting next before have IND them for how you of so

Scott Wolchko

going terrific to I think learn a question have ASH wait to about to It’s more that. for you're and

Unidentified Analyst

or terms a are on developing strategic how Great. internally? derived there it of these in iPSC develop to If you FT-XXX any ask like may path thinking partnering modalities I preparing is is

Scott Wolchko

We're planning internally. on it developing

Therapeutics of best that Sloan our move striking the medical open we in in the behind positioned given the and Miller side. this on Michelle very the to of XX believe on with t-cell top history are centers today partnership developing the our that Fate are NK we iPSC side thinking platform own although cell absolutely Sadelain to We the years forward was Memorial cell and with Minnesota that on investigators and and partnerships Jeff forming collaboration University Kettering and

Operator

question Capital Do next from BMO with comes Kim Our Markets.

Your line is open.

Do Kim

on ProTmune, that GVL range balance you to GvHD could prior believe you a doesn't question talk also achieves you of the of about GvHD incidence mentioned couple the rates activity? but the A of that compromise reducing

Scott Wolchko

take can a at I first. Sure. that crack

to getting reduce are potential GRFS setting. the with the transplant where occurs the essentially with yet GvHD is relapse respect in discussed to we question looking the you your of the and for heart deal at think the cancer also endpoint mortality I potential what overall to that

historical as setting So his mentioned XX% GRFS be in are remarks rates appear range. to in during to Chris seen the in I studies think the prepared this XX% success that

than patients patients of XX% to of meet and So more that about half Day of at relapse surviving at free, only criteria do XXX to and free the continues GvHD down being year. trend not one

historically totality depending is and XX% that So objective. only we really XX% when we the into to severe timeframe look at GvHD achieve about mortality patients taking the on of transplant what the consideration relapse see

Do Kim

of rates be to of Okay. or historical Phase-X will transplants expected in one the these that And is percentage would ASH patients and data to cut the relapse patients by time the relapse what of it the surprising kind see off? relapsed

Scott Wolchko

six, the during more respect three, sloping following curve can So evenly GvHD to relapse meaning occur first and has XX relapse than and a slower occur incidence with nine transplant. does months

a from six and out XXX. that GvHD call flatten occur very evenly more to occurs begins So period by to it to and trail is phenomenon Day throughout does respect begin does to suddenly with one XXX day occurs off early, year. incidence months the Relapse

still. window relapse extend to months the nine keep we eye an that on certainly So to an keep does and really on from eye six

Do Kim

And does positive that how and we and CDXX administering the of that consider cells you're patient positive number to affect should the about CDX we think when what outcome? patient Okay.

Scott Wolchko

aligned we graft care for standard entire molecules, just CDXX where and minimum then patient adhere the is and to to just possible hours the then of graft, of we'll standard then the the requirements small entire to basically all mobilized just four and it have the to we as closely So we administer like entire again this wash it possible. two administered model so we closely take normal have graft, care the with aligned as

Chris Storgard

mean numbers reducing that. not We're we're you're t-cells we of now, I are doing the if is question

graft, we're graft. then We a graft preferable standard mobilized care, modulating blood we that that are administering are and mobile accepting of

So to cell with reduction that going no or cell is the t-cells. is separation respect there XXs or on

Do Kim

are Thank longer looking final at you. CMV priority? activation and no a is [ph] question still -- or you Okay. is One that infection

Chris Storgard

and are of they It's as track one will the objectives well although the not study to infection lead we to mortality. CMV continue do important rates infections main of as because

Operator

next H.C. ED question Our with comes Wainwright. White from

Your line is open.

ED White

and in you well? of to FT-XXX for be you filed the had as any and said we in FT-XXX INDs those IND filed repeated us the quarter So we just guidance give FT-XXX, Can expect on first on that is the expected 'XX. XXXX should

Scott Wolchko

So previously expect middle IND that said for on half Memorial t-cell begin derived product little that early to it's still comfortable filing Sloan are in give XXXX we FT-XXX IPS first we respect a conversation With that timeline. FT-XXX in too us an and very the CAR tech-transfer the guidance we XXXX comfortable of although with for Kettering first for filing IND will manufacture. have we certainly of in the we're to to the

ED White

to embargo XX be with before time? Day questions off you did does not at ProTmune due And I've occurrence the as the might happen of the that the end to then Day on answer of the the GvHD XX one able between but the cut patient next the

Scott Wolchko

to answering available reviewed going DMC is available answer including the if we're the time Day to they is data the Phase what beyond the did reviewed that to think they the refrain Phase-X question all data data from I yes Phase-X X time was data the obviously. at have all review your question question at XX

ED White

the Okay. patient just a with had or there the latest coincidence a the is maybe GvHD? it's that And engraftment then know correlation just you neutrophil

Scott Wolchko

that. anything read not into would I

Operator

showing to Wolchko the Scott turn further call I'm for would back now further remarks. no I like any questions. to

Scott Wolchko

to seeing you that in everyone Thank at and participating of much today's for weeks call a look Thank about half ASH. end very week at forward a couple everyone we you. week after the and in

Operator

participating program. Ladies conference. today's in thank and This for the concludes gentlemen you

have wonderful You a may day. all disconnect. Everyone